Idiopathic Orthostatic Hypotension and other Autonomic Failure Syndromes Medication
- Author: Mohini Gurme, MD; Chief Editor: Selim R Benbadis, MD more...
Medication Summary
Several medications are available to help manage symptoms of autonomic dysfunction. The most commonly used are listed below.
Mineralocorticoids
Class Summary
These agents play a role in hemodynamics and can be used to control orthostatic hypotension.
Fludrocortisone (Florinef)
Used to increase standing blood pressure. Acts to increase sodium retention and expand plasma volume.
Alpha-adrenergic agonists
Class Summary
These agents improve the hemodynamic status by increasing myocardial contractility and heart rate, resulting in increased cardiac output. They also increase peripheral resistance by causing vasoconstriction. Increased cardiac output and increased peripheral resistance lead to increased blood pressure.
Midodrine (ProAmatine)
Alpha-adrenergic agonist used in orthostatic hypotension to increase standing blood pressure. Acts at level of resistance vessels and is useful for peripherally mediated hypotension.
Beta-adrenergic blocking agents
Class Summary
These agents limit heart rate and reduce blood pressure.
Propranolol (Inderal)
Nonselective beta-blocker that is lipophilic (penetrates CNS).
Vasopressors
Class Summary
These agents augment both coronary and cerebral blood flow that occurs during the low flow state associated idiopathic hypotension.
Desmopressin (DDAVP, Stimate)
Increases cellular permeability of collecting ducts, resulting in reabsorption of water by kidneys. Helpful for symptoms of nocturia.
Erythropoietins
Class Summary
Anemia may occur due to low blood levels of endogenous erythropoietin, which can result from a lack of sympathetic innervation. Erythropoietins may also increase blood pressure through other mechanisms.
Epoetin alfa (Epogen, Procrit)
Stimulates RBC production in bone marrow. Increases sensitivity to pressor effects of angiotensin II, intravascular volume, cytosolic free calcium in vascular smooth muscle, and plasma endothelin level. Enhances renal tubular reabsorption.
Gastroprokinetic agents
Class Summary
These agents promote motility of the GI tract.
Metoclopramide (Reglan)
Dopamine agonist helpful in relieving GI paresis.
Anticholinesterase inhibitors
Class Summary
These agents inhibit acetylcholinesterase (AChE), raising the concentration of ACh at cholinergic synapses and increasing the chance of activating the AChR.
Pyridostigmine bromide (Mestinon)
Stimulates muscarinic AChR, increasing salivation and gastric motility.
Bulk agents
Class Summary
Used for the chronic treatment of constipation.
Psyllium (Metamucil, Fiberall)
Must be taken with water or may cause obstruction. Increase dose gradually. Inform patient that effect not immediate.
Antispasmodic agents
Class Summary
These agents may be helpful for urinary symptoms.
Oxybutynin (Ditropan)
Useful for urinary urgency. Inhibits action of ACh on smooth muscle and direct antispasmodic effect on smooth muscle, which increases bladder capacity and decreases uninhibited contractions.
Cholinergic agents
Class Summary
These agents stimulate cholinergic receptors in the smooth muscle of the urinary bladder for stimulation of bladder emptying.
Bethanechol hydrochloride (Duvoid, Urecholine)
For selective stimulation of the bladder to produce contraction to initiate micturition and empty bladder. Most useful in bladder hypotonia. Rarely used because of GI stimulation and difficulty in timing effect.
Phosphodiesterase inhibitors
Class Summary
These oral agents act peripherally to induce smooth muscle relaxation of the corpora cavernosa.
Sildenafil (Viagra)
Selective PDE5 inhibitor that inactivates cGMP, attenuating vasodilatory effect of NO. Effective in mild-to-moderate erectile dysfunction. Patient should take on an empty stomach about 1 h before sexual activity. Sexual stimulation necessary to activate response. Increased sensitivity for erections may last 24 h.
Corticosteroids
Class Summary
These agents regulate key factors in the immune system.
Prednisone (Deltasone, Orasone, Meticorten)
Shorten duration of symptoms and improves overall prognosis in acute pandysautonomia.
Immune globulins
Class Summary
These agents are used to improve clinical and immunologic aspects of the disease. May decrease autoantibody production, and increase solubilization and removal of immune complexes.
Immune globulins intravenous (IVIG, Gammagard, Gamimune)
Shortens duration of symptoms and improves overall prognosis in acute pandysautonomia. Clinical improvements have been reported within few days of administration, with normalization of autonomic parameters.
Neutralize circulating myelin antibodies through antiidiotypic antibodies; down-regulates proinflammatory cytokines, including INF-gamma; blocks Fc receptors on macrophages; suppresses inducer T and B cells and augments suppressor T cells; blocks complement cascade; promotes remyelination; may increase CSF IgG (10%).
Sithinamsuwan P, Orrawanhanothai P, Thithum K, Udommongkol C, Chairangsaris P, Chinvarun Y, et al. Orthostatic hypotension: a non-motor complication assessment in 82 patients with idiopathic Parkinson's disease in Phramongkutklao Hospital. J Med Assoc Thai. Nov 2010;93 Suppl 6:S93-9. [Medline].
Yu X, Stavrakis S, Hill MA, Huang S, Reim S, Li H, et al. Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an "autoimmune" orthostatic hypotension. J Am Soc Hypertens. Jan-Feb 2012;6(1):40-7. [Medline]. [Full Text].
Klein CM, Vernino S, Lennon VA, et al. The spectrum of autoimmune autonomic neuropathies. Ann Neurol. 2003;53:752-8. [Medline].
Sandroni P, Vernino S, Klein CM, et al. Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol. Jan 2004;61(1):44-8. [Medline].
Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. Feb 1 1999;163(1):94-8. [Medline].
Sommer C, Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol. Jul 2007;6(7):632-42. [Medline].
Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. Feb 7 2008;358(6):615-24. [Medline].
Schroeder C, Vernino S, Birkenfeld AL, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. Oct 13 2005;353(15):1585-90. [Medline].
Heafield MT, Gammage MD, Nightingale S, Williams AC. Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet. Jan 6 1996;347(8993):28-9. [Medline].
Quan D, Rich MM, Bird SJ. Acute idiopathic dysautonomia: electrophysiology and response to intravenous immunoglobulin. Neurology. Feb 8 2000;54(3):770-1. [Medline].
Gibbons C, Vernino S, Freeman R. Combined immunomodulation therapy in autoimmune autonomic ganglionopathy. Arch Neurol. Feb 2008;65(2):213-217.
Bannister R, Mathias CJ, Polinsky R. Autonomic failure--A comparison between UK and US experience. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. New York, NY: Oxford University Press; 1988:282-8.
Daniel SE. The neuropharmacology and neurochemistry of multiple system atrophy. In: Autonomic Failure: A Textbook of Disorders of the Autonomic Nervous System. New York, NY: Oxford University Press; 1992:564-85.
Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G. Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR. Clin Auton Res. Dec 2007;17(6):334-40. [Medline].
Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. Apr 1996;6(2):125-6. [Medline].
Mathias CJ. Disorders of the autonomic nervous system. In: Neurology in Clinical Practice. Boston, Mass: Butterworth-Heinemann; 1996:1953-81.
Matthews MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In: Autonomic Failure: A Textbook of Disorders of the Autonomic Nervous System. New York, NY: Oxford University Press; 1992:593-621.
Quinn NP, Wenning G, Marsden CD. The Shy-Drager syndrome. What did Shy and Drager really describe?. Arch Neurol. Jul 1995;52(7):656-7. [Medline].
Smit AA, Vermeulen M, Koelman JH, Wieling W. Unusual recovery from acute panautonomic neuropathy after immunoglobulin therapy. Mayo Clin Proc. Apr 1997;72(4):333-5. [Medline].
Suarez GA, Fealey RD, Camilleri M, Low PA. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology. Sep 1994;44(9):1675-82. [Medline].
van Ingelghem E, van Zandijcke M, Lammens M. Pure autonomic failure: a new case with clinical, biochemical, and necropsy data. J Neurol Neurosurg Psychiatry. Jun 1994;57(6):745-7. [Medline].
Vernino S, Freeman R. Peripheral Autonomic Neuropathies. Continuum Lifelong Learning Neurol. Dec 2007;13(6):89-110.

